ESMO 2024: Targeting the Treatment Challenges of Small Cell Lung Cancer - Episode 4
Immunotherapy in Limited-Stage SCLC
Panelists discuss how the timing of consolidation therapy with a PD-L1 inhibitor after completion of chemoradiotherapy in limited-stage SCLC small cell lung cancer can vary from immediately to 6six weeks, while also exploring the potential for curative-intent immunotherapy with durvalumab, the role of SBRT cCRT concurrent chemoradiotherapy followed by durvalumab, and insights from the ADRIATIC clinical trial regarding the use of PCI in this patient population.
Video content above is prompted by the following:
Dr Iams: In patients with limited-stage small cell lung cancer (LS-SCLC), what would you consider to be a reasonable time interval between completion of concurrent chemoradiotherapy (cCRT) to the initiation of consolidation therapy with a PD-L1 inhibitor?
- Please discuss your thoughts on the range of time prior to initiating therapy, from immediately to 6 weeks post cCRT.
[All Faculty]: What is the potential for curative-intent immunotherapy with durvalumab for earlier stages of SCLC?
- What is the role of SBRT in earlier stages of disease vs cCRT followed by durvalumab?
Dr Leal: How do the data from the ADRIATIC clinical trial inform us about the use of PCI in patients with LS-SCLC?
Related Content:
